Antidote competitors

Antidote Competitors include Durect, Amarin, BTG and Zogenix.
Add company...
Antidote
Antidote
Antidote is accelerating the breakthroughs of new treatments by bridging the gap between medical research and the people who need them.
Durect
Durect
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.
Amarin
Amarin
Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease.
BTG
BTG
BTG is an international specialist healthcare company.
Zogenix
Zogenix
Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.
Founding Date
Founding Date
2009
Founding Date
N/A
Founding Date
1991
Founding Date
1948
Founding Date
2006
Type
Type
Private
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Tags
Locations
Locations
London, GB HQ
New York, US
Carmel, US
Locations
Cupertino, US HQ
Locations
Dublin, IE HQ
Bedminster Township, US
Locations
London, GB HQ
Rosedale, AU
Ottawa, CA
Düsseldorf, DE
Hong Kong , HK
Ataşehir, TR
Surrey, GB
see more
Locations
Emeryville, US HQ
Windsor And Maidenhead, GB
Employees
Employees
537% decrease
Employees
903% decrease
Employees
530120% increase
Employees
N/A
Employees
68
Valuation ($)
Valuation ($)
N/A
Valuation ($)
122.3 m
Valuation ($)
6.3 b
Valuation ($)
N/A
Valuation ($)
2.2 b
Twitter followers
Twitter followers
1
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
786
Twitter followers
475

Financial

Revenue (est.)
Revenue (est.)
£2.2m (FY, 2017)
Revenue (est.)
$18.6m (FY, 2018)
Revenue (est.)
$229.2m (FY, 2018)
Revenue (est.)
£620.5m (FY, 2018)
Revenue (est.)
N/A
Cost of goods
Cost of goods
£892.3k (FY, 2017)
Cost of goods
N/A
Cost of goods
$54.5m (FY, 2018)
Cost of goods
£185.9m (FY, 2018)
Cost of goods
N/A
Gross profit
Gross profit
£1.3m (FY, 2017)
Gross profit
N/A
Gross profit
$174.7m (FY, 2018)
Gross profit
£434.6m (FY, 2018)
Gross profit
N/A
Net income
Net income
(£4.6m) (FY, 2017)
Net income
($25.3m) (FY, 2018)
Net income
($116.4m) (FY, 2018)
Net income
£12.7m (FY, 2018)
Net income
($123.9m) (FY, 2018)

Funding

Total funding raised
Total funding raised
$ 17.9m
Total funding raised
$ 20m
Total funding raised
$ 70m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Durect
HQ
Cupertino, US
Employees
90↓ 3% decrease

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.

View company
Amarin
HQ
Dublin, IE
Employees
530

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease.

View company
BTG
HQ
London, GB

BTG is an international specialist healthcare company.

View company
Zogenix
HQ
Emeryville, US
Employees
68

Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.

View company